|
|
Nektar Therapeutics -Announces $300M Public Offering
|
|
|
|
HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $165
|
|
|
|
BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $151
|
|
|
|
12 Health Care Stocks Moving In Tuesday's Intraday Session
|
|
|
|
Nektar Therapeutics Stock Is Trending Tuesday: What's Going On?
|
|
|
|
Datadog, Spotify, Marriott, Ferrari And Other Big Stocks Moving Higher On Tuesday
|
|
|
|
Nektar Therapeutics shares are trading higher after the company announced results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin.
|
|
|
|
Nektar Says REZOLVE-AD Week 52 Data Show Rezpegaldesleukin Maintained EASI-75 In 71% And 83% And vIGA-AD 0/1 In 85% And 63% With Monthly And Quarterly 24 µg/kg Dosing
|
|
|
|
Where Nektar Therapeutics Stands With Analysts
|
|
|
|
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $118 Price Target
|
|